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Therapy with 3-hydroxy-3-methylglutaryl coenzyme A
(HMG-CoA) reductase inhibitors, or statins, has proven to
be effective in the treatment of lipid disorders. However,
statin therapy continues to be underused, even though
statins are a relatively safe and well-tolerated class of
agents. In this study, we assessed trends in lipid control in
patients with heart disease who receive most of their
health care in primary care clinics. The objective was to
determine whether systems of care implemented within a
large medical group are associated with improved treat-
ment and control of dyslipidemia in a high-risk group of
coronary heart disease patients.
Methods
All adults with heart disease in a Minnesota medical
group (N = 2947) were identified using diagnosis and pro-
cedure codes related to coronary heart disease (sensitivity
= 0.85; positive predictive value = 0.89) in 1996. Study sub-
jects were observed from 1995 to 1998. Subjects had a
baseline and follow-up test for low-density lipoprotein cho-
lesterol and high-density lipoprotein cholesterol. Changes
between baseline and follow-up measurements and trends
in the use of statins and other lipid-active agents among
the study subjects were analyzed.
Results
Among 1388 subjects with two or more eligible lipid
measurements, mean low-density lipoprotein cholesterol
improved from 137.6 mg/dL to 111.0 mg/dL (P < .001), and
mean high-density lipoprotein cholesterol improved from
42.3 mg/dL to 46.3 mg/dL (P < .001). The percentage of
patients with low-density lipoprotein cholesterol <100
mg/dL rose from 12.5% to 39.8% (P < .001), and the per-
centage with high-density lipoprotein cholesterol >40
mg/dL rose from 52.5% to 67.6% (P < .001). In multivari-
ate models, statin use was identified as the main factor
that contributed to the improvement in low-density
lipoprotein cholesterol (P < .001). Men had greater
decreases in low-density lipoprotein cholesterol than
women after adjusting for other variables (P < .001).
Statin use rose from 24.3% at baseline to 69.6% at follow-
up. The statin discontinuation rate was 8.3% for baseline
statin users and 12.2% for subjects who used statins at any
time during the study period.
Conclusion
Investment in better heart disease care for patients in
primary care clinics led to major improvement in lipid
control over 30 months, primarily due to increased statin
use. Improvements in low-density lipoprotein cholesterol
and high-density lipoprotein cholesterol were sufficient to
substantially reduce risk of subsequent major cardiovas-
cular events.
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Introduction
Clinical trials provide strong support for using 3-
hydroxy-3-methylglutaryl coenzyme A (HMG-CoA) reduc-
tase inhibitor (statin) therapy in patients with coronary
heart disease (CHD) (1-7). Statins are a relatively safe and
well-tolerated class of agents that have proven to be 
effective in treating lipid disorders. Recent data suggest,
however, that statin therapy remains underused in the
treatment of lipid disorders, or dyslipidemia. Reasons for
this underuse of statins include inadequate physician
titration of medications to reach the goal level of low-den-
sity lipoprotein cholesterol (LDL-C) recommended by the
National Cholesterol Education Program (NCEP) and
inadequate long-term patient adherence to prescribed
drug therapy (8-10).
In this study, we assessed trends in the use of statin
therapy and changes in LDL-C levels in a well-defined
population of adults with CHD receiving their care at a
single large multispecialty medical group. During the 4-
year study period, the medical group emphasized the
importance of lipid control in CHD patients. Primary care
physicians had unrestricted access to several statins
through the medical group’s drug formulary. Clinical
guidelines for lipid control emphasized aggressive phar-
macotherapy, and patients received messages on the
importance of lipid control through periodic medical group
publications sent to their homes. Our study objective was
to determine whether systems of care implemented within
a large medical group are associated with improved treat-




The study was conducted at HealthPartners Medical
Group (HPMG), a large multispecialty group practice in
Minnesota established in 1957 that in 1998 provided care
to 220,000 patients insured by HealthPartners. Patients
received clinical care at one of 18 primary care clinics
staffed by internal medicine and family practice physicians.
About 75% of CHD patients at HPMG have pharmaceu-
tical benefits as part of their health insurance. Most
patients with such benefits had a copayment of $10 to $15
for each 30-day supply of a prescription medication during
the study period. Most patients without pharmaceutical
benefits were aged 65 years or older and chose not to have
such coverage because of the additional monthly premium
required. There were no other out-of-pocket costs to plan
members or disincentives to physicians for measuring
serum lipids or prescribing lipid treatment as desired. The
medical group formulary included unrestricted physician
prescribing of statins. During the study period, lovastatin
(Mevacor), fluvastatin (Lescol), pravastatin (Pravachol),
simvastatin (Zocor), and atorvastatin (Lipitor), along with
a wide selection of other lipid active agents — including
gemfibrozil (Lopid), niacin preparations, and cholestyra-
mine — were available for unrestricted use.
Local clinical practice guidelines for lipid screening and
treatment were implemented in 1995 and updated annu-
ally through the Institute for Clinical Systems
Improvement (ICSI), a collaborative health improvement
organization organized and supported by HealthPartners
and many other Minnesota health care organizations,
including the Park Nicollet Clinic, Allina Medical Clinic,
and the Mayo Clinic. ICSI lipid treatment guidelines (11)
are similar to those of NCEP (12) and, at the time of the
study, emphasized aggressive pharmacotherapy for
patients with CHD to reduce LDL-C levels to <100 mg/dL. 
Study subjects
Study subjects were adult patients identified as having
CHD in 1996. A diagnosis of CHD was assigned to any
patient meeting at least one of the following criteria in
1996: at least two diagnoses from among codes
410.xx–414.xx or 429.2 in the International Classification
of Diseases, Ninth Revision, Clinical Modification
(ICD-9-CM); at least one procedure from among codes
33510–33545 and 36822 in Current Procedural
Terminology (CPT); or at least one procedure from among
codes 36.0–36.29 and 36.9–36.99 in the International
Classification of Diseases, Ninth Revision (ICD-9). This
process of identifying study subjects has been formally
assessed and has an estimated sensitivity of 0.85, speci-
ficity of 0.99, and positive predictive value of 0.89 (13).
Each eligible study subject was aged 19 years or older on
January 1, 1996, and was continuously enrolled for care at
HPMG during the 1996 calendar year. This process iden-
tified 2947 eligible patients with heart disease in 1996.
The study was reviewed, approved, and monitored by the
HealthPartners Institutional Review Board.
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Trends in lipid control were necessarily based on
change in LDL-C levels from a baseline test to a follow-
up test. The baseline test was defined as the first LDL-C
test done on or after January 1, 1995. The follow-up test
was defined as the most recent LDL-C test done before
December 31, 1998. Furthermore, the follow-up LDL-C
test must have been done at least 365 days after the
baseline measurement. Thus, for eligible baseline and
follow-up data, a study subject must have had at least
two LDL-C measures at least 365 days apart between
January 1, 1995, and December 31, 1998. Of 2947 eligi-
ble study subjects aged 19 years or older with CHD, a
total of 1388 (47%) had two qualifying LDL-C measure-
ments recorded during the specified time period. Among
the 1559 without two qualifying LDL-C measures, 155
died or disenrolled by December 31, 1998. Changes in
high-density lipoprotein cholesterol (HDL-C) were also
measured using the same definition of test dates and
period between tests.
To explore associations between changes in LDL-C and
statin use from administrative data, we defined a second
subpopulation. We analyzed data on individuals with two
qualifying LDL-C measurements and pharmacy coverage
provided by HealthPartners. There were 1038 in this sub-
population (75% of study subjects with two LDL-C meas-
urements). Pharmacy coverage was defined as present
from baseline to follow-up LDL-C tests, allowing for a gap
in coverage of up to 60 days during that period.
All lipid tests during the study period were performed at
a single accredited clinical chemistry laboratory using
standard assay methods (14-16) that did not change dur-
ing the study period. Values of LDL-C were calculated in
milligrams per deciliter (mg/dL) using the Friedewald for-
mula (17). The fasting period prior to taking the blood
sample was recorded along with each test result; only
LDL-C values drawn after a minimum 12-hour fast were
used in this study. Levels of HDL-C directly measured in
mg/dL using a standard assay were also obtained from
automated laboratory databases. Changes in LDL-C or
HDL-C from baseline to follow-up were calculated as the
follow-up LDL-C (or HDL-C) minus the baseline level. A
negative number thus represents improvement in LDL-C
over time, and a positive number represents improvement
in HDL-C over time. 
All identified CHD patients were surveyed by mail with
a telephone follow-up (18) in 1998 to assess demographic
variables, such as age, sex, height, weight, educational
level, smoking status, and aspirin use; 2122 (72%) of the
2947 study-eligible members returned surveys with com-
plete responses on these variables.
Administrative data were used to identify patients with
CHD and their age, sex, pharmacy coverage, filled 
prescriptions for statins, and filled prescriptions for other
cholesterol-acting agents. For all patients with pharmacy
coverage, pharmacy databases provided name of medica-
tion, dose per tablet, number of tablets dispensed, and the
dispense date. For multivariate analysis, we measured
statin use as the portion of the days between the baseline
and follow-up LDL-C measures for which the subject had
a filled statin prescription. We measured the use of other
cholesterol-acting agents (“other use”) in the same man-
ner. These agents included fibrates, resins, nicotinic acid,
probucol, and oral estrogens. Over-the-counter niacin for-
mulations were not tracked on the pharmacy database.
Lipid tests and results were available from electronic data-
bases, as was information on health plan enrollment.
Plan of analysis
Initial analysis was done to assess the distributions of
baseline LDL-C, follow-up LDL-C, change in LDL-C, and
other lipid measures. Differences in demographic vari-
ables between participants with and without two qualify-
ing LDL-C measurements were analyzed using two-sam-
ple t tests for continuous variables and chi-square tests for
count variables. The Satterthwaite adjustment for
unequal variances in two-sample tests was used when
appropriate. Changes over time in continuous variables
were analyzed using the single-sample t test of the differ-
ence between baseline and follow-up for continuous vari-
ables and the McNemar test for count variables.
Multivariate linear regression was used to estimate rela-
tionships between the difference in baseline and follow-up
LDL-C as well as the difference in HDL-C as the key
dependent variables. In all analyses, a two-tailed α of 0.05
was used to test for significant associations.
Results
The overall population of individuals with at least two
qualifying LDL-C measures (n = 1388) is described in
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Table 1. Although baseline and follow-up lipid measures
were required to be at least 365 days apart, the median
time between the measures was 917 days, or 2.5 years.
The mean age of study subjects with two qualifying
LDL-C measures was 64.9 years; 66.6% were male, and
24.1% had a college degree. Current smoking was report-
ed by 7.1%, and 59.4% indicated a prior history of smoking.
Regular aspirin use was reported by 82.9%. Mean body
mass index (BMI) was 27.1 kg/m2, and 24.3% were identi-
fied as having diabetes at baseline. There were statistical-
ly significant differences between study-eligible members
with and without two qualifying LDL-C measurements for
all variables other than BMI and baseline diabetes.
Table 2 describes LDL-C and HDL-C measures at base-
line and at follow-up. Data are presented for all patients
with qualifying LDL-C measurements (n = 1388), for
patients with baseline LDL-C >100 mg/dL (n = 1214), and
for patients with baseline LDL-C >130 mg/dL (n = 781). For
all patients with qualifying measurements, there was a sig-
nificant decline in mean LDL-C, from 137.6 mg/dL at base-
line to 111.0 mg/dL at follow-up, a change of −26.6 mg/dL
(P < .001). Mean HDL-C also improved, with an increase
from 42.3 mg/dL at baseline to 46.3 mg/dL at follow-up, a
change of +4.0 mg/dL (P < .001). For the subgroup with
baseline LDL-C >100 mg/dL, mean LDL-C decreased from
144.7 mg/dL at baseline to 113.5 mg/dL at follow-up, a
change of −31.2 mg/dL (P < .001). Mean HDL-C in this sub-
group increased from 42.8 mg/dL to 46.6 mg/dL, a change
of +3.8 mg/dL (P = .008). For the subgroup with baseline
LDL-C >130 mg/dL, the change in mean LDL-C was −42.5
mg/dL (P< .001), and the change in HDL-C was +3.5 mg/dL
(P = .02). The percentage of patients in the study with LDL-
C <100 mg/dL rose from 12.5% to 39.8% (P < .001), and the
percentage of patients with HDL-C >40 mg/dL rose from
52.5% to 67.6% (P < .001).
Table 3 shows the proportion of patients receiving
statins (among the 1038 subjects with pharmacy coverage
and two qualifying LDL-C measures) at both baseline and
follow-up and the subsequent discontinuation rate more
than 1 year later in two groups of statin users: patients
who used statins at baseline and patients who used statins
at any time during the study period. Statin use among all
study subjects in this group was 24.3% at baseline and
69.6% at follow-up. In those with baseline LDL-C >100
mg/dL, statin use was 21.0% at baseline and 70.4% at fol-
low-up. In those with baseline LDL-C >130 mg/dL, statin
use was 16.7% at baseline and 74.2% at follow-up. Statin
discontinuation rates were 8.3% for baseline statin users,
9.5% for baseline users whose baseline LDL-C was >100
mg/dL, and 4.1% for baseline statin users whose baseline
LDL-C was >130 mg/dL. For subjects who used statins at
any time during the study period, the discontinuation rate
was 12.2%.
Table 4 reports the multivariate analysis of LDL-C and
HDL-C changes and statin use for the 1038 study-eligible
members with pharmacy coverage. The model presented
in Table 4 includes administrative data only. The model
presented in Table 5 adds survey data and is limited to the
804 individuals included in the previous model who
returned surveys with completed responses on variables of
interest. Residual plots showed neither excessive nonnor-
mality in the residuals nor heteroskedasticity.
In the models of Table 4, baseline LDL-C, sex, and statin
use are significant predictors of decreases in LDL-C. Table
5 shows that use of statins for the entire period between
baseline and follow-up measures (i.e., statin use = 1.0) was
associated with an additional 17 mg/dL decrease in LDL-
C compared with no statin use. On average, men experi-
ence an additional 7 mg/dL decrease in LDL-C compared
with women. Only baseline HDL-C and sex are signifi-
cantly related to changes in HDL-C. On average, women
experienced a 1.7 mg/dL greater increase in HDL than did
men. Among the variables collected from surveys (Table
5), aspirin use was associated with a statistically signifi-
cant (6 mg/dL) decrease in LDL-C, and a 1-point decrease
in BMI was associated with a 0.29 mg/dL improvement in
HDL-C.
Discussion
We analyzed trends in LDL-C and HDL-C levels in
patients with diagnosed heart disease having two LDL-C
measurements in a large medical group. Statin use was
analyzed for the subgroup of 1038 (75%) with pharmacy
coverage. At baseline, all patients had established CHD
and hence would have had an NCEP-established goal of
LDL-C <100 mg/dL at the time of the study. However, at
baseline only 24.3% were receiving statin therapy, and
only 12.5% had LDL-C of <100 mg/dL. After a mean fol-
low-up period of 2.5 years, mean LDL-C and HDL-C lev-
els had significantly improved in the entire cohort, as well
as in subgroups stratified by baseline LDL-C of >130
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marked increase in statin use during the follow-up period,
with a significant increase in patients achieving the study
goal of LDL-C <100 mg/dL (12.5% at baseline vs 39.8% at
follow-up, P < .001).
These data document a significant improvement in the
proportion of CHD patients treated with statins and reach-
ing their NCEP-established LDL-C goal in the late 1990s
(19-21). Our results favorably compare with contemporane-
ous data collected on the general Minnesota population,
which showed worsening cholesterol levels in the 1990s (8).
Results also favorably compare with the survey of 48,586
individuals with coronary artery disease from practices
throughout the United States, chosen for their frequent use
of cholesterol-active medications, in which 44% had annual
testing of LDL-C. Of those who had annual testing, only
25% reached the target LDL-C of <100 mg/dL, and only
39% were taking lipid lowering therapy (9).
The Lipid Treatment Assessment Project (L-TAP) was a
comprehensive survey of lipid therapy prescribing habits
and lipid results conducted in five regions of the United
States and drawn from a group of primary care physicians,
also targeted because they wrote large numbers of pre-
scriptions for lipid-active drugs (10). The L-TAP study
demonstrated that in a cohort of 1460 patients with CHD,
only 18% attained the NCEP-established goal of LDL-C
<100 mg/dL, compared with 39.8% in our study who
attained an LDL-C level of <100 mg/dL. This was despite
the fact that 84.6% received treatment with lipid lowering
agents, compared with 69.6% receiving statin therapy in
our study (10).
While baseline LDL-C levels were being measured for
this study (median date of October 12, 1995), a system-
wide program of health-related goals was implemented at
HPMG. Among these goals was a heart-health goal that
called for a 25% reduction in CHD events within 4 years
(22). The importance of lipid control in CHD patients was
emphasized by medical group leaders in meetings with
primary care physicians and certain subspecialty physi-
cians, including cardiologists.
During the years of this study, systems of care were
developed and deployed within the medical group to sup-
port both patient and provider attention to control of lipid
disorders (22-26). Results of lipid testing were stored for
electronic retrieval via computer. Lipid test results, with
an explanation and recommendations, were mailed to
patients. High-risk patient registries that included adults
with CHD or diabetes and LDL-C test results or indicated
a need to obtain an LDL-C test were provided to clinics
and physicians as an aid for tracking, visit planning, and
active outreach. One of the authors (RJG) gave a series of
lectures at each medical group clinic about the use and
benefits of lipid-lowering therapy. Also, a specialized pro-
gram known as Lifestyle Management was added to the
cardiac rehabilitation program. This program featured
one-on-one sessions with nursing staff for patients and fol-
low-up case management, as well as a direct review of each
patient’s care plan and progress by the medical director.
During the study period, it also became commonplace to
initiate statin therapy before hospital discharge following
an acute cardiac event, such as a myocardial infarction.
These programs, initiated to aggressively reduce cardio-
vascular events in high-risk patients during the study
period, likely accounted for some of the observed improve-
ment in lipid control. It is unlikely that secular trends
accounted for all the improvement, because few other med-
ical groups have achieved similar levels of lipid drug use
(27) or lipid control (28), and lipid trends in Minnesota
during these years were not improving (8).
Several factors limit the interpretation of the data pre-
sented here. First, misclassification of CHD status is a pos-
sibility; however, we used a validated method for heart dis-
ease identification with an estimated sensitivity of 0.85
and a positive predictive value of 0.89 (13). Second, the
study was limited to one large medical group in
Minnesota. Studies in a variety of other settings may be
needed to replicate and extend the findings reported here.
Finally, the requirement that each patient have at least
two LDL-C measurements over an average 30-month peri-
od may have identified a population of patients having
more active management of dyslipidemia. However, this
selection strategy was essential, given our intent to assess
trends of LDL-C and statin use over time. We were unable
to compare patients with and without qualifying LDL-C
measures in relation to baseline LDL-C levels or statin
use. We observed at least one LDL-C in only a portion of
those without two LDL-C measurements, and the majori-
ty of the single LDL-C measures that exist were observed
near the end of the 4-year study period. Therefore, the
available LDL-C measures for the group excluded from 
the analysis do not provide an analogous baseline 
LDL-C measure. Likewise, our measure of statin 
use is tied to LDL-C baseline and follow-up measures 
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and could not be computed for participants without two
qualifying measures.
We conclude that substantial improvement in LDL-C
and HDL-C control occurred in adults with CHD at this
practice site during the late 1990s. The main cause of the
improvement was a dramatic increase in statin use, which
was significantly related to LDL-C change. However, other
factors contributed to improved lipid control in this popu-
lation, including coordination of use of clinical guidelines
among clinics, use of high-risk patient registries, and use
of automated monitoring and prioritizing of patients for
special attention. As LDL-C goals become more stringent
(3,4,6), the application of effective outpatient chronic dis-
ease care strategies such as registries, active outreach,
visit planning, and coordination of care across sites will
increase in importance. These data show that primary
care clinics and providers are capable of dramatic improve-
ments in care over a short period and suggest that
resources invested to improve outpatient care can rapidly
return a sizeable clinical return on investment.
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Tables
Table 1. Characteristics of Adult Health Plan Members With Coronary Heart Disease (N = 2947), by LDL-C Test Status, 1996a
Mean age (years) 64.9 68.4 <.001
Male 66.6 52.3 <.001
Baseline diabetes 24.3 25.0 .67
College degree (2307) 24.1 18.3 .001
Current smokers (2193) 7.1 10.5 .005
Former smokers (2193) 59.4 50.7 <.001
Regular aspirin use (2201) 82.9 65.8 <.001
Mean BMIc (2097) 27.1 26.8 .15
BMI >25 (2097) 72.2 63.9 <.001
BMI >30 (2097) 24.5 26.0 .43
aValues are percentages unless otherwise indicated. LDL-C indicates low-density lipoprotein cholesterol.
bSample size for each survey variable when different from N shown in parentheses. 
cBMI indicates body mass index (kg/m2).
Table 2. Change in LDL-C and HDL-C Among Adult Health Plan Members With Two Qualifying LDL-C Measurements,
1995–1998a
All subjects (n=1388)
LDL-C (mean mg/dL) 137.6 111.0 −26.6 <.001
HDL-C (mean mg/dL) 42.3 46.3 +4.0 <.001
LDL-C <100 mg/dL (% subjects) 12.5 39.8 +27.3 <.001
HDL-C >40 mg/dL (% subjects) 52.5 67.6 +15.1 <.001
Subjects with baseline LDL-C >100 mg/dL (n=1214)
LDL-C (mean mg/dL) 144.7 113.5 −31.2 <.001
HDL-C (mean mg/dL) 42.8 46.6 +3.8 .008
LDL-C <100 mg/dL (% subjects) 0 36.2 +36.2 NA
HDL-C >40 mg/dL (% subjects) 54.5 68.4 +13.9 <.001
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Members With Two Qualifying  Members Without Two Qualifying
LDL-C Measurements  LDL-C Measurements
Characteristicb (n = 1388)  (n = 1559) P
Characteristic Baseline Follow-up Change P
(Continued on next page)Subjects with baseline LDL-C >130 mg/dL (n=781)
LDL-C (mean mg/dL) 160.8 118.3 −42.5 <.001
HDL-C (mean mg/dL) 43.8 47.3 +3.5 .02
LDL-C <100 mg/dL (% subjects) 0 31.4 +31.4 NA
HDL-C >40 mg/dL (% subjects) 58.5 72.6 +14.1 <.001
aLDL-C indicates low-density lipoprotein cholesterol; HDL-C, high-density lipoprotein cholesterol; and NA, not applicable.
Table 3. Statin Use Among Adult Health Plan Members With Coronary Heart Disease, Two Qualifying LDL-C Measurements,
and Pharmacy Coverage (n = 1038), 1995–1998a
All subjects (n=1038) 24.3 69.6 +45.3 <.001 8.3 12.2
Baseline LDL-C >100 mg/dL (n=899) 21.0 70.4 +49.4 <.001 9.5 12.8
Baseline LDL-C >130 mg/dL (n=563) 16.7 74.2 +57.5 <.001 4.1 12.3
aLDL-C indicates low-density lipoprotein cholesterol.
Table 4. Multivariate Analysis of Changes in LDL-C and HDL-C Among Adult Health Plan Members (n = 1038) in Relation to
Statin Use and Baseline Lipid Levels, With Adjustment for Demographicsa
Intercept 90.38 7.465 <.001 14.53 2.013 <.001
Baseline LDL-C 0.69 0.025 <.001 NA NA NA
Baseline HDL-C NA NA NA 0.28 0.022 <.001
Days between baseline and follow-up 0.0015 0.003 .62 0.0000029 0.0008647 .997
Statin use 17.18 2.238 <.001 0.67 0.639 .29
Use of other cholesterol-acting drugs 5.32 2.881 .07 1.48 0.8295 .08
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Table 2. (continued) Change in LDL-C and HDL-C Among Adult Health Plan Members With Two Qualifying LDL-C
Measurements, 1995–1998a
Characteristic Baseline Follow-up Change P
Statin Discontinuation Rates 
Statin Use Before Follow-up
Baseline Users During 
Baseline (%) Follow-up (%) Change (%)  P Users (%) Study Period (%)
Change in LDL-Cb Change in HDL-Cb
Coefficient Standard Coefficient  Standard 
Variable Estimate Error P Estimate Error P
(Continued on next page)VOLUME 2: NO. 3
JULY 2005
Age 0.10 0.087 .25 0.027 0.025 .28
Male 7.36 2.056 <.001 1.67 0.625 .007
Adjusted R2 0.459 NA NA 0.142 NA NA
F value 147.9 NA <.001 29.6 NA <.001
aLDL-C indicates low-density lipoprotein cholesterol; HDL-C, high-density lipoprotein cholesterol. These health plan members had two qualifying LDL-C meas-
ures plus pharmacy coverage. This model includes administrative data only.
bChanges in LDL-C and HDL-C are measured as the follow-up value minus the baseline value. NA indicates not applicable.
Table 5. Multivariate Analysis of Changes in LDL-C and HDL-C in Relation to Statin Use and Baseline Lipid Levels Among Adult
Health Plan Members (n = 804), With Adjustment for Demographics and Selected Cardiovascular Disease Risk Factorsa
Intercept 88.73 12.351 <.001 25.19 3.462 <.001
Baseline LDL-C 0.69 0.028 <.001 NA NA NA
Baseline HDL-C NA NA NA 0.31 0.025 <.001
Days between baseline and follow-up 0.0026 0.0034 .45 0.00040 0.00096 .67
Statin use 17.08 2.541 <.001 1.44 0.707 .04
Use of other cholesterol-acting drugs 4.04 3.273 .22 1.47 0.915 .11
Age 0.025 0.109 .81 0.00057 0.0304 .99
Male 7.32 2.490 .003 2.51 0.751 <.001
Current smoker 5.87 3.851 .13 0.87 1.077 .42
Former smoker 1.22 2.191 .58 0.99 0.613 .11
BMIc 0.058 0.213 .79 0.29 0.060 <.001
Regular aspirin use 5.91 2.640 .03 0.43 0.738 .56
High school diploma 4.33 2.328 .06 0.58 0.652 .37
College degree 1.94 2.568 .45 0.43 0.600 .55
Adjusted R2 0.452 NA NA 0.174 NA NA
F value 56.2 NA <.001 15.1 NA <.001
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Table 4. (continued) Multivariate Analysis of Changes in LDL-C and HDL-C Among Adult Health Plan Members (n = 1038) in
Relation to Statin Use and Baseline Lipid Levels, With Adjustment for Demographicsa
Change in LDL-Cb Change in HDL-Cb
Coefficient Standard Coefficient  Standard 
Variable Estimate Error P Estimate Error P
Change in LDL-Cb Change in HDL-Cb
Coefficient Standard Coefficient  Standard 
Variable Estimate Error P Estimate Error P
(Footnotes on next page)aLDL-C indicates low-density lipoprotein cholesterol; HDL-C, high-density lipoprotein cholesterol. These health plan members had two qualifying LDL-C meas-
ures plus pharmacy coverage, and they completed health surveys. This model includes administrative data as well as subject survey data.
bChanges in LDL-C and HDL-C are measured as the follow-up value minus the baseline value. NA indicates not applicable.
cBMI indicates body mass index (kg/m2).
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